About Juvaris BioTherapeutics
Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The Company's platform technology induces immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate is JVRS-100, which is currently in clinical development as a vaccine adjuvant and an immunotherapeutic.
Missing: Juvaris BioTherapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Juvaris BioTherapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Juvaris BioTherapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Juvaris BioTherapeutics is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Juvaris BioTherapeutics Patents
Juvaris BioTherapeutics has filed 1 patent.
Vaccines, Ribosomal proteins, Vaccination, Viral diseases, Virology
Vaccines, Ribosomal proteins, Vaccination, Viral diseases, Virology
Latest Juvaris BioTherapeutics News
Nov 28, 2016
Juvaris BioTherapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 01:28 EST 28 Nov 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Juvaris BioTherapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Juvaris BioTherapeutics , Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Juvaris BioTherapeutics, Inc. since January 2007. Key Findings Provides intelligence on Juvaris BioTherapeutics, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Juvaris BioTherapeutics, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Juvaris BioTherapeutics, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Juvaris BioTherapeutics, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Juvaris BioTherapeutics Frequently Asked Questions (FAQ)
When was Juvaris BioTherapeutics founded?
Juvaris BioTherapeutics was founded in 2003.
Where is Juvaris BioTherapeutics's headquarters?
Juvaris BioTherapeutics's headquarters is located at 866 Malcolm Road, Burlingame.
What is Juvaris BioTherapeutics's latest funding round?
Juvaris BioTherapeutics's latest funding round is Series B - II.
How much did Juvaris BioTherapeutics raise?
Juvaris BioTherapeutics raised a total of $40.98M.
Who are the investors of Juvaris BioTherapeutics?
Investors of Juvaris BioTherapeutics include Kleiner Perkins Caufield & Byers and SV Health Investors.
Who are Juvaris BioTherapeutics's competitors?
Competitors of Juvaris BioTherapeutics include ISA Pharmaceuticals, FluGen, CoImmune, Bellicum Pharmaceuticals, Mucosis and 12 more.
Compare Juvaris BioTherapeutics to Competitors
Theraclone Sciences, formerly Spaltudaq, is a biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The companys technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human subjects. Human monoclonal antibodies can be rapidly isolated using the ISTAR discovery platform and scaled for industrial production. Such human antibody drug candidates may be uniquely safe and relevant to combating disease across broad patient populations.
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
ISA Pharmaceuticals (Immune System Activation) is dedicated to fighting cancer and infectious diseases by providing ways to activate the patients immune system. Building on the work by internationally renowned tumor-immunology researcher Professor Kees Melief at the Leiden University Medical Center, the Netherlands, ISA Pharmaceuticals focuses on the development of synthetic peptide vaccines that boost the bodys immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. Thanks to a recent by the Melief-group, clinical studies (phase I/II) are showing highly promising results. The is the use of long peptides in therapeutic vaccines. This synthetic long peptide concept (SLP)aims to enable the activation of both cytotoxic T-cells (killer cells) and T-helper cells, which leads to activity of the immune systems against a tumor.
Favrille is a developer of cancer and autoimmune disease immuno-therapeutics.
ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.
Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.